Table 4. Analysis of factors affecting biological treatment process.

	Continued as it was before		Stopped all of the medications		Stopped only biological and synthetic therapy		Decreased or skipped the dose of biological therapy		p
	n	%	n	%	n	%	n	%
Working status									0.983
Employed	104	63.8	20	12.3	15	9.2	24 (14.7)	14.7
Unemployed	4	80.0	0	0	0	0	1 (20.0)	20.0
Housewife	37	68.5	6	11.1	4	7.4	7 (13.0)	13.0
Retired	33	67.3	7	14.3	3	6.1	6 (12.2)	12.2
Need to go out for work									0.135
Unable to go to work	75	69.4	13	12.0	8	7.4	12 (11.1)	11.1
due to pandemic Be able to go to work	29	52.7	7	12.7	7	12.7	12 (21.8)	21.8
Comorbid disease
No comorbidity	126	68.9	19	10.4	11	6.0	27	14.8	0.130
Hypertension	32	66.7	4	8.3	4	8.3	8	16.7	0.799
Diabetes mellitus	10	58.8	3	17.6	3	17.6	1	5.9	0.326
Cardiovascular disease	11	78.6	1	7.1	2	14.3	0	0	0.328
Pulmonary disease	3	60.0	2	40.0	0	0	0	0	0.222
Smoking status									0.855
Active	66	67.3	11	11.2	6	6.1	15	15.3
Quit	44	68.8	8	12.5	4	6.3	8	12.5
Never	68	63.0	14	13.0	12	11.1	14	13.0
Rheumatic diseases									0.096
Spondyloarthritis	148	65.5	31	13.7	15	6.6	32	14.2
Rheumatoid arthritis	30	66.7	2	4.4	7	15.6	6	13.3
Medications									0.731
Anti-tumor necrosis factor	161	66.8	28	11.6	19	7.9	33	13.7
Non-TNF biological DMARDs	17	56.7	5	16.7	3	10.0	5	16.7
Receiving infusion therapy									0.001*
Yes	24	44.4	8	14.8	7	13.0	15	27.8
No	153	70.8	25	11.6	15	6.9	23	10.6
History of contact with
COVID-19 patients	8	50.0	5	31.3	1	6.3	2	12.5	0.121
Yes	178	66.7	28	11.0	21	8.2	36	14.1
No
Diagnosed with COVID-19									0.221
Yes	1	33.3	1	33.3	1	33.3	0	0
No	177	66.0	32	11.9	21	7.8	38	14.2
TNF: Tumor necrosis factor; DMARDs: Disease-modifying anti-rheumatic drugs; * p<0.05, Chi-square test.